Social Entrepreneurship in Pakistan: Challenges and Prospects

Social Entrepreneurship (SE) benefits the society by helping to achieve social and economic goals. SE is receiving scholarly attention around the globe but its development is still moderate in Pakistan. Despite the growing trend, the dominant focus of scholars remains the ideological debate about the meaning and definition of SE. Such an approach inhibits the exploration of its other facets. Casting the gap in literature, this paper aims to find out the challenges and prospects that social entrepreneurs face in their journey, specifically in Pakistan. Keeping in view the emerging importance of this sector, this study discusses the findings of 14 in-depth semi-structured interviews conducted with leading social entrepreneurs, practitioners and academicians related to the field to understand the phenomenon at hand. Drawing upon the findings of the study, useful insights have been put forth as its theoretical contribution. Moreover, local and national government can benefit from the findings to enhance consciousness regarding the fourth sector of the economy, eventually augmenting the available social capital

Entrepreneurial Finance: Exploring the Drivers and Challenges Faced by Young Pakistani Entrepreneurs

Within the last decade, the popularity of entrepreneurship rose exponentially all over the world; however, research in this field within the context of developing countries is still lacking. Generally speaking, accessibility and availability of financial support is one of the most significant factors affecting an entrepreneur’s venture when it is in its initial stages. This is especially true in the case of developing countries such as Pakistan. For this reason, this study explored the drivers and challenges faced by Pakistani entrepreneurs regarding the access to and availability of financial support. Data was collected through 65 semi-structured interviews of budding Pakistani entrepreneurs until the saturation point was reached. Afterwards, the interviews were transcribed and imported to NVivo 12 plus, which was used to conduct a thematic analysis of the interviews. The major findings of the research revealed that entrepreneurs face many challenges with regards to the access and availability of financial support in Pakistan. Additionally, according to the respondents, the entrepreneurial journey in Pakistan is laden with challenges and has minimum drivers (opportunities available to the entrepreneurs). The respondents also expressed a lack of awareness and downright distrust of the government-sponsored financial support schemes.&nbsp

WORKPLACE BULLYING: CASE STUDY OF PUBLIC SECTOR UNIVERSITY

Workplace bullying is an amalgamation of negative behaviors of varying intensity that can severely damage one‟s ability to work effectively or efficiently. The study aims to examine the prevalence, forms and perceived perpetrator(s) of workplace bullying in a public sector university, ultimately highlighting the existing policies and procedures aiming to discourage the practice of workplace bullying at an organizational level. The study adopts a mixed method strategy. A two-step sampling approach is adopted for gathering quantitative data, where stratified sampling was followed by simple random sampling technique. For qualitative data, purposive sampling is used. The study identifies that workplace bullying prevails among university‟s faculty members where more than half of the respondents were exposed to it. The perceived perpetrators were mostly male employees targeting male employees on the same  hierarchical level. Also, faculty members belonging from the middle age and those who are at the middle of their career experienced highest exposure to bullying at work

Factors Leading To Early Versus Late Presentation In Patients With Neck Masses

Abstract Objective: To compare the factors that lead to early versus late presentation in patients with neck masses Study Design: Group Comparative Study. Study Setting & Duration: Department of Otorhinolaryngology and Head &Neck Surgery at Rawalpindi Teaching Hospital from 01-9-2022 to 01-03-2023. Methods: Approval of the study was obtained from the hospital's ethical committee. A total of 64 patients (32 in each group) were placed in two Groups A &  B. Group A included patients who presented early and Group B included patients who presented late. Both male and female patients were selected. In this study patients suffering from neck masses who have reported for work-up to the Department of ENT, Rawalpindi Teaching Hospital, and fulfil the complete inclusion and exclusion criteria were included. Patients were selected via consecutive nonprobability sampling. The data were analyzed for frequencies by SPSS 24. Results: A total of 64 patients were included in this study. The mean age of these patients was 48.67 ± 9.74 years, ranging from 25 to 70 years. The Frequency distribution of males at 65.63 % was found to be more than that of females at 34.36 %. In the majority of patients, the size of mass more than 1.5 cm (51.56%) revealed malignancy, while only a small percentage of patients (48.44%) had less than 1.5 cm neck mass. The majority of patients (93.75%) with addiction presented late, while just a small number (6.25%) had early presentation. The majority of patients (51.56%) with frequent visits to  Quacks /Hakeem per year were presented late. Regarding socioeconomic status, the majority of patients (28) from upper-class families presented early, compared to (11) patients from middle-class families who presented late, and all (21) patients from lower-class families who presented late. The education level reveals that the majority of patients (31), who were educated, attended a school for more than a year, but only up to ten (matriculate or similar) years, or advanced literacy: got a college- or university-level education, and they displayed early presentation. The 30 uneducated patients, who never attended an educational institution, or attended for less than one year, presented late. 31 patients had frequent visits to health care professionals and were presented early, 30 patients had fewer visits to health care professionals present late with advanced disease.  Conclusion: The majority of patients who were drug and alcohol addicts were presented late with advanced disease. Middle-class families, lower-class families, uneducated patients, and patients who did not see a healthcare provider four or more times per year, make up the majority of visits to Quacks and Hakeem each year and are presented late with advanced disease as compared to the group of patients who belong to upper class, were literate with no history of drug or alcohol addiction and have frequent visits to health care professionals. Both groups were considered to be significant (p=0.00) based on the probability ratio. This study helped to identify the role of various suspected risk factors for late presentation in head and neck cancers in an attempt to reinforce or negate their importance which will help to guide the formation of screening protocols thereby improving morbidity, and mortality and reducing financial costs.

Measurement of Acefylline Piperazine Interaction and Dissociation Constants in Polymer Solvent Systems

In this study the physicochemical interactions of acefylline piperazine drug (APD) were examined in aqueous and aqueous polymer systems viz., aqueous polyethylene glycol (1.0 %w/v) and aqueous polyvinyl pyrrolidone (1.0% w/v). The study was carried within the concentration ranges from 2.0×10-2 to 10.0 ×10-2 mol/dm3 at different temperatures (293.15 to 318.15 K with the difference of 5 K). Various analytical methods such as conductometric, refractometry, and liquid chromatographic (RP-HPLC) were applied. In order to observe the interaction of APD, was calculated to evaluate the structural influence of polymers on the mobility of solute (APD) at different temperatures. α, Kd and Walden product of APD were also assessed in aqueous polyethylene glycol and aqueous polyvinyl pyrrolidone. Solvation was observed by Walden's product showing strong solvation of APD in water-soluble polymer systems. Thermodynamic parameters for APD such as , ΔG*, ΔH*and ΔS* have also been evaluated as a function of temperature to determine the exo/endothermic nature of the drug dissociation process. Specific refraction, molar refraction and polarizability of APD in aqueous and aqueous polymer systems were calculated using the Lorentz-Lorentz equation and various interactions were interpreted. Drug's compatibility studies were also performed by HPLC in aqueous and aqueous polymer systems

Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial

Background: Tranexamic acid reduces surgical bleeding and reduces death due to bleeding in patients with trauma. Meta-analyses of small trials show that tranexamic acid might decrease deaths from gastrointestinal bleeding. We aimed to assess the effects of tranexamic acid in patients with gastrointestinal bleeding. Methods: We did an international, multicentre, randomised, placebo-controlled trial in 164 hospitals in 15 countries. Patients were enrolled if the responsible clinician was uncertain whether to use tranexamic acid, were aged above the minimum age considered an adult in their country (either aged 16 years and older or aged 18 years and older), and had significant (defined as at risk of bleeding to death) upper or lower gastrointestinal bleeding. Patients were randomly assigned by selection of a numbered treatment pack from a box containing eight packs that were identical apart from the pack number. Patients received either a loading dose of 1 g tranexamic acid, which was added to 100 mL infusion bag of 0·9% sodium chloride and infused by slow intravenous injection over 10 min, followed by a maintenance dose of 3 g tranexamic acid added to 1 L of any isotonic intravenous solution and infused at 125 mg/h for 24 h, or placebo (sodium chloride 0·9%). Patients, caregivers, and those assessing outcomes were masked to allocation. The primary outcome was death due to bleeding within 5 days of randomisation; analysis excluded patients who received neither dose of the allocated treatment and those for whom outcome data on death were unavailable. This trial was registered with Current Controlled Trials, ISRCTN11225767, and ClinicalTrials.gov, NCT01658124. Findings: Between July 4, 2013, and June 21, 2019, we randomly allocated 12 009 patients to receive tranexamic acid (5994, 49·9%) or matching placebo (6015, 50·1%), of whom 11 952 (99·5%) received the first dose of the allocated treatment. Death due to bleeding within 5 days of randomisation occurred in 222 (4%) of 5956 patients in the tranexamic acid group and in 226 (4%) of 5981 patients in the placebo group (risk ratio [RR] 0·99, 95% CI 0·82–1·18). Arterial thromboembolic events (myocardial infarction or stroke) were similar in the tranexamic acid group and placebo group (42 [0·7%] of 5952 vs 46 [0·8%] of 5977; 0·92; 0·60 to 1·39). Venous thromboembolic events (deep vein thrombosis or pulmonary embolism) were higher in tranexamic acid group than in the placebo group (48 [0·8%] of 5952 vs 26 [0·4%] of 5977; RR 1·85; 95% CI 1·15 to 2·98). Interpretation: We found that tranexamic acid did not reduce death from gastrointestinal bleeding. On the basis of our results, tranexamic acid should not be used for the treatment of gastrointestinal bleeding outside the context of a randomised trial

Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial

BackgroundTranexamic acid reduces surgical bleeding and reduces death due to bleeding in patients with trauma. Meta-analyses of small trials show that tranexamic acid might decrease deaths from gastrointestinal bleeding. We aimed to assess the effects of tranexamic acid in patients with gastrointestinal bleeding.MethodsWe did an international, multicentre, randomised, placebo-controlled trial in 164 hospitals in 15 countries. Patients were enrolled if the responsible clinician was uncertain whether to use tranexamic acid, were aged above the minimum age considered an adult in their country (either aged 16 years and older or aged 18 years and older), and had significant (defined as at risk of bleeding to death) upper or lower gastrointestinal bleeding. Patients were randomly assigned by selection of a numbered treatment pack from a box containing eight packs that were identical apart from the pack number. Patients received either a loading dose of 1 g tranexamic acid, which was added to 100 mL infusion bag of 0·9% sodium chloride and infused by slow intravenous injection over 10 min, followed by a maintenance dose of 3 g tranexamic acid added to 1 L of any isotonic intravenous solution and infused at 125 mg/h for 24 h, or placebo (sodium chloride 0·9%). Patients, caregivers, and those assessing outcomes were masked to allocation. The primary outcome was death due to bleeding within 5 days of randomisation; analysis excluded patients who received neither dose of the allocated treatment and those for whom outcome data on death were unavailable. This trial was registered with Current Controlled Trials, ISRCTN11225767, and ClinicalTrials.gov, NCT01658124.FindingsBetween July 4, 2013, and June 21, 2019, we randomly allocated 12 009 patients to receive tranexamic acid (5994, 49·9%) or matching placebo (6015, 50·1%), of whom 11 952 (99·5%) received the first dose of the allocated treatment. Death due to bleeding within 5 days of randomisation occurred in 222 (4%) of 5956 patients in the tranexamic acid group and in 226 (4%) of 5981 patients in the placebo group (risk ratio [RR] 0·99, 95% CI 0·82–1·18). Arterial thromboembolic events (myocardial infarction or stroke) were similar in the tranexamic acid group and placebo group (42 [0·7%] of 5952 vs 46 [0·8%] of 5977; 0·92; 0·60 to 1·39). Venous thromboembolic events (deep vein thrombosis or pulmonary embolism) were higher in tranexamic acid group than in the placebo group (48 [0·8%] of 5952 vs 26 [0·4%] of 5977; RR 1·85; 95% CI 1·15 to 2·98).InterpretationWe found that tranexamic acid did not reduce death from gastrointestinal bleeding. On the basis of our results, tranexamic acid should not be used for the treatment of gastrointestinal bleeding outside the context of a randomised trial.</div